This review provides a summary of presentations from the 2020 virtual European Hematology Association (EHA)-Scientific Working Group (SWG) Scientific Meeting on Immunotherapy for Hematological Disorders. The session focussed on the T-cell Ig and mucin domain containing protein-3 (TIM-3) receptor and its potential as a new target for drug development in the treatment of patients with higher-risk myelodysplastic syndrome (MDS).
EMJ Hematology 9 [Supplement 1] . 2021
April 2021
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/04/Niamh-OConnell-Thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/Pier-Mannucci-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/Immunoglobin-D-Multiple-Myeloma-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/02/Coexistence-of-Sickle-Cell-Thalassaemia-with-Overlapping-Syndrome-940x564.png)